Oncternal Therapeutics
ONCT · NASDAQ
$0.5266−$0.1673 (−24.11%)TodayMarket closed ·
No price history for this range.
About ONCT
- Employees
- 29
- Headquarters
- San Diego, California
- Listed
- Feb 3, 2004
- Sector
- Health Care
- Industry
- Biotechnology
- Website
- oncternal.com
Leadership
| Name | Title | Since |
|---|---|---|
| David Hale | — | — |
| James Breitmeyer | — | 2019 |
| Richard Vincent | — | — |
| Rajesh Krishnan | — | — |
| Chase Leavitt | — | — |
| Michael Carter | — | — |
| Jill Desimone | — | — |
| Daniel Kisner | — | — |
| William Larue | — | — |
| Rosemary Mazanet | — | — |
| Charles Theuer | — | — |
| Robert Wills | — | 2015 |
Suppliers and customers
Price correlation is over one year: 1 means the stocks move together, -1 opposite
| Company | Relationship | Correlation |
|---|---|---|
| Shanghai Pharm Hldg H | Supplier and customer | 0.67 |
| Celularity A CELU | Supplier and customer | 0.10 |
| AbbVie ABBV | Supplier and customer | -0.90 |
| University of Texas M.D. Anderson Cancer Center | Supplier and customer | — |
| State of California | Customer | — |
| United States | Customer | — |
| Georgetown University | Supplier and customer | — |
| University of California | Supplier and customer | — |
| University of Tennessee | Supplier and customer | — |
| Miltenyi Biotec GmbH | Supplier and customer | — |
Similar companies
Companies in the same industry as Oncternal Therapeutics
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.